Advancing Genetic Treatments Against Blindness
Paris-based GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy based treatments of retinal degenerative diseases.
Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to (i) prevent retinal degeneration in selected pathological conditions and (ii) to restore vision in patients suffering from very low vision or blindness.
Founded in 2012, the company is building on its close relationship with José Sahel, Botond Roska, Ernst Bamberg, Jean Bennett, Luk Vandenberghe and Connie Cepko, six of the world’s most renowned leading experts in this field and co-founders of GenSight Biologics.
Our strategic vision is to become the leader in gene therapy for ophthalmology diseases. We aim to develop, on the basis of our technology and know-how in the field of AAV vectors, optogenetics and genetic disorders, innovative therapeutic products that could avoid sight loss or restore vision in patients suffering from various forms of retinal degeneration.
Vision loss is the most feared consequence of disease apart from death. There are 15 million people in the Western world suffering from blindness or very limited vision, with few, if any treatments. Very limited vision and blindness are associated with very high costs (current estimates are more than €200 billion in the EU alone).
November 4-6, 2013: Gensight Biologics will present at BioEurope 2013, Vienna, Austria
On the occasion of the 19th annual international partnering conference, Gensight's presentation is confirmed on Tuesday, November 5, 10:30 am, Room: Schubert 4 on level 1.
Gensight will attend the partnering and meet with a numerous partners and companies, willing to know about our promising products under development and their innovative technologies, to prevent sight loss and restore vision
October 2, 2013: Gensight, EuropaBio's Top 5 most innovative European biotech in 2013
Entering its 4th year, the EuropaBio Most Innovative EU Biotech SME Award 2013 selected top 5 candidates from which Gensight belongs to.
The award has grown rapidly each year to reach a wider audience across members states, with applications coming from all three sectors of biotechnology - healthcare, industrial and agricultural, all providing solutions to major societal unmet needs.
This year, the award was presented during the first ever European Biotechnology Week, at an event in Brussels which discussed Europe’s role in the booming biotech sector, in comparison with global trends.
April 9, 2013: GenSight Biologics Raises €32m in a Series A Financing for Ophthalmic Gene Therapy
The financing was co-led by Novartis Venture Fund, Abingworth LLP, Versant Ventures and Index Ventures. GenSight will use the funds to develop a gene replacement therapy for Leber’s hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).